Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
China Isotope & Radiation Corp. ( (HK:1763) ) has issued an announcement.
CIRC has announced a significant technological breakthrough in the production of carbon isotope products, specifically high-abundance 13CO gas, which is crucial for urea breath tests detecting Helicobacter pylori infections. This advancement positions China among the few countries capable of producing these materials, reducing reliance on imports and enhancing the nation’s research and production capabilities in stable isotope technology. Additionally, CIRC has started phase II construction of its stable isotope base project, which will ensure a stable supply of these materials, contributing to public health improvements and supporting the Healthy China Initiative.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
More about China Isotope & Radiation Corp.
China Isotope & Radiation Corporation (CIRC) operates in the medical isotope industry, focusing on the production of isotopes and related products. The company is known for its development and control over the entire industrial chain for breath test products, specifically targeting the healthcare sector with products for gastrointestinal disease treatments.
Average Trading Volume: 269,425
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.12B
See more insights into 1763 stock on TipRanks’ Stock Analysis page.